HER-2, hormone receptor type linked to breast cancer outcomes

12/18/2007 | Reuters

Breast cancer patients who are both HER-2 positive and hormone receptor-negative are at a higher risk for recurrence after chemotherapy treatment, according to new research from the Mayo Clinic. The brain is the most common site of recurrence, the study showed.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN